Dapagliflozin in the Treatment of Heart Failure
NCT05727423 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 45
Last updated 2024-01-29
Summary
prospectively evaluation the safety and efficacy of the Sodium-glucose Cotransporter-2 (SGLT2) inhibitor dapagliflozin in non-diabetic patients with heart failure and a reduced ejection fraction
Conditions
Sponsors & Collaborators
-
Helwan University
lead OTHER
Eligibility
- Min Age
- 19 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-09-01
- Primary Completion
- 2024-01-28
- Completion
- 2024-02-01
Countries
- Egypt
Study Locations
More Related Trials
-
Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI
NCT06009874 ·Status: RECRUITING ·Phase: NA
-
Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy
NCT04575675 ·Status: COMPLETED ·Phase: PHASE4
-
Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial
NCT04304560 ·Status: UNKNOWN ·Phase: PHASE2
-
Empagliflozin on Patients With Preserved Heart Failure
NCT07112274 ·Status: COMPLETED ·Phase: NA
-
Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction
NCT05849766 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Dapagliflozin on VT in Patients With Heart Failure.
NCT05550441 ·Status: UNKNOWN ·Phase: PHASE4
-
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
NCT02653482 ·Status: COMPLETED ·Phase: PHASE4
-
Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy
NCT05795400 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation
NCT06740786 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure
NCT06783166 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
NCT04564742 ·Status: COMPLETED ·Phase: PHASE3
-
Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients
NCT05957887 ·Status: RECRUITING ·Phase: PHASE3
-
Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients
NCT05424315 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List
NCT04782245 ·Status: WITHDRAWN ·Phase: PHASE2
-
Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction
NCT05420285 ·Status: UNKNOWN ·Phase: PHASE2
-
Dapagliflozin at Discharge on Hospital Heart Failure Readmission
NCT04249778 ·Status: COMPLETED ·Phase: PHASE4
-
Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure
NCT05776043 ·Status: RECRUITING ·Phase: PHASE3
-
DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
NCT03877237 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure
NCT04956809 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Dapagliflozin on Patients With Cardiomyopathy
NCT07076615 ·Status: RECRUITING ·Phase: PHASE4
-
The Fontan Dapagliflozin Pilot Study
NCT05741658 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction
NCT04475042 ·Status: UNKNOWN ·Phase: PHASE2
-
Dapagliflozin (DAPA) Effects in HFpEF
NCT04730947 ·Status: COMPLETED ·Phase: PHASE2
-
Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
NCT03030235 ·Status: COMPLETED ·Phase: PHASE4
-
Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM)
NCT05848102 ·Status: UNKNOWN ·Phase: PHASE4